Aromatase Inhibitor–Related Symptoms Reported by Postmenopausal Women with Nonmetastatic, Estrogen Receptor–Positive Breast Cancer: A Systematic Review
Open Access
- 21 August 2023
- journal article
- review article
- Published by Elsevier in Seminars in Oncology Nursing
- Vol. 39 (5) , 151487
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomesInternational Journal of Clinical Oncology, 2015
- Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)JNCI: Journal of the National Cancer Institute, 2014
- Classification of and Risk Factors for Estrogen Deprivation Pain Syndromes Related to Aromatase Inhibitor Treatments in Women With Breast Cancer: A Prospective Multicenter Cohort StudyThe Journal of Pain, 2014
- Symptoms overlooked in hospitalized cancer patients: Impact of concurrent symptoms on overlooked by nursesPalliative and Supportive Care, 2013
- Anastrozole-Associated Joint Pain and Other Symptoms in Patients With Breast CancerThe Journal of Pain, 2013
- Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs)Breast Cancer Research and Treatment, 2011
- Health care providers underestimate symptom intensities of cancer patients: A multicenter European studyHealth and Quality of Life Outcomes, 2010
- Quality of life issues in relation to the aromatase inhibitorThe Journal of Steroid Biochemistry and Molecular Biology, 2007
- Enhancing Research on Cancer SurvivorsJournal of Clinical Oncology, 2006
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993